PERTH, Australia – Chimeric Therapeutics Ltd. has acquired exclusive worldwide rights to develop and commercialize the City of Hope Cancer Center’s chlorotoxin chimeric antigen receptor cell therapy.
PERTH, Australia – Sydney-based Chimeric Therapeutics Ltd. has acquired exclusive worldwide rights to develop and commercialize the City of Hope Cancer Center’s chlorotoxin chimeric antigen receptor cell therapy that uses a peptide derived from scorpion toxin to direct T cells to target glioblastoma.
BEIJING – Cross-border biotech Denovo Biopharma LLC, based in San Diego, the U.S. and Hangzhou, China, closed a series C funding round on June 29 to pocket ¥590 million (US$83.5 million).
HONG KONG –Shanghai-based Zai Lab Ltd. has won an approval for the first innovative treatment for glioblastoma approved by China in more than 15 years, with the National Medical Products Administration’s nod for Optune in combination with temozolomide for use in patients with newly diagnosed glioblastoma.
HONG KONG –Shanghai-based Zai Lab Ltd. has won an approval for the first innovative treatment for glioblastoma approved by China in more than 15 years, with the National Medical Products Administration’s (NMPA) nod for Optune in combination with temozolomide for use in patients with newly diagnosed glioblastoma (GBM), and also as a monotherapy for the treatment of patients with recurrent GBM.
PERTH, Australia – Sydney-based Kazia Therapeutics Ltd. reported interim data showing that lead candidate paxalisib (formerly GDC-0084) saw a positive overall survival signal in its phase II glioblastoma trial, and the company raised AU$7.2 million (US$4.4 million) days after the data were released.
TORONTO – If Toronto’s Sunnybrook Hospital and the W. Garfield Weston Foundation get their way, a CA$33 million (US$24 million) initiative unveiled March 2 dramatically will increase patient access to made-to-measure ultrasound technology for penetrating the blood-brain barrier to treat Alzheimer's disease and brain cancer.
Aivita Biomedical Inc.’s CEO, Hans Keirstead, just finished up a $12.5 million fundraiser and he’s prepping for another $12.5 million in a second effort. In the two months since he started raising the money, he has hired four more people and plans to hire four more by year-end, bringing the company’s headcount to 36 employees.
Lantheus Holdings Inc., of North Billerica, Mass., has entered a strategic collaboration with Paris-based Carthera SAS for the use of its microbubbles in combination with Carthera’s investigational Sonocloud system. The implantable device is in development for the treatment of recurrent glioblastoma, a fast-growing brain tumor with a post-diagnosis median survival of just 15 months. The new deal furthers two of Lantheus’ strategic goals, finding new applications for its microbubbles and expanding its footprint in oncology.
PERTH, Australia – Sydney-based Kazia Therapeutics Ltd.’s shares soared nearly 82% this week on positive interim results for lead molecule GDC-0084 in a phase II glioblastoma trial. Data from the first nine patients in the study show that GDC-0084 treatment resulted in a median progression-free survival (PFS) rate of 8.4 months compared to the standard of care, temozolomide, which has a PFS of around 5.3 months.
